Cargando…
T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621511/ http://dx.doi.org/10.1097/01.HS9.0000890968.53519.f4 |
| _version_ | 1784821573311528960 |
|---|---|
| author | Diefenbach, Catherine Jegede, Opeyemi Ambinder, Richard Cohen, Jonathon Robertson, Michael David, Kevin Advani, Ranjana Fenske, Timothy Barta, Stefan Palmisiano, Neil Svoboda, Jakub Morgan, David Karmali, Reem Kahl, Brad Ansell, Stephen M. |
| author_facet | Diefenbach, Catherine Jegede, Opeyemi Ambinder, Richard Cohen, Jonathon Robertson, Michael David, Kevin Advani, Ranjana Fenske, Timothy Barta, Stefan Palmisiano, Neil Svoboda, Jakub Morgan, David Karmali, Reem Kahl, Brad Ansell, Stephen M. |
| author_sort | Diefenbach, Catherine |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621511 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96215112022-11-01 T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I) Diefenbach, Catherine Jegede, Opeyemi Ambinder, Richard Cohen, Jonathon Robertson, Michael David, Kevin Advani, Ranjana Fenske, Timothy Barta, Stefan Palmisiano, Neil Svoboda, Jakub Morgan, David Karmali, Reem Kahl, Brad Ansell, Stephen M. Hemasphere Relapsed/Refractory Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621511/ http://dx.doi.org/10.1097/01.HS9.0000890968.53519.f4 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Relapsed/Refractory Diefenbach, Catherine Jegede, Opeyemi Ambinder, Richard Cohen, Jonathon Robertson, Michael David, Kevin Advani, Ranjana Fenske, Timothy Barta, Stefan Palmisiano, Neil Svoboda, Jakub Morgan, David Karmali, Reem Kahl, Brad Ansell, Stephen M. T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I) |
| title | T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I) |
| title_full | T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I) |
| title_fullStr | T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I) |
| title_full_unstemmed | T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I) |
| title_short | T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I) |
| title_sort | t100: long term follow-up of a phase i study combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory hodgkin lymphoma: a trial of the ecog-acrin research group (e4412: arms a-i) |
| topic | Relapsed/Refractory |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621511/ http://dx.doi.org/10.1097/01.HS9.0000890968.53519.f4 |
| work_keys_str_mv | AT diefenbachcatherine t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT jegedeopeyemi t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT ambinderrichard t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT cohenjonathon t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT robertsonmichael t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT davidkevin t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT advaniranjana t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT fensketimothy t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT bartastefan t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT palmisianoneil t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT svobodajakub t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT morgandavid t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT karmalireem t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT kahlbrad t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai AT ansellstephenm t100longtermfollowupofaphaseistudycombinationsofipilimumabnivolumabandbrentuximabvedotininpatientswithrelapsedrefractoryhodgkinlymphomaatrialoftheecogacrinresearchgroupe4412armsai |